Biomarker Core

生物标志物核心

• 批准号: 10601069
• 负责人: Sterling C Johnson
• 金额: $ 47.89万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10601069
• 关键词: Adopted; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-42; Amyloid beta-Protein; Anatomy; Atrophic; Biological Assay; Biological Markers; Blood flow; Brain; Brain imaging; Cataloging; Cerebrospinal Fluid; Cerebrovascular Disorders; Charge; Clinical; Collaborations; Collection; Communities; Consultations; Data; Data Analyses; Data Set; Development; Disease; Ensure; Etiology; Evaluation; Future; Goals; Grant; Image; Impaired cognition; Individual; Inflammation; Infrastructure; Joints; Lewy Body Disease; Light; Link; Liquid substance; Machine Learning; Magnetic Resonance Imaging; Methods; Modality; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Neurofibrillary Tangles; Neuronal Injury; Outcome; Perfusion; Positron-Emission Tomography; Preparation; Prevention strategy; Process; Process Assessment; Protocols documentation; Qualifying; Research; Research Design; Research Personnel; Risk Factors; Secure; Senile Plaques; Site; Standardization; Symptoms; Synapses; Techniques; Time; Tracer; Universities; Vascular Diseases; Walking; White Matter Hyperintensity; Wisconsin; Work; alpha synuclein; analytical method; brain health; cohort; community center; data management; density; empowerment; image processing; imaging biomarker; in vivo; ischemic lesion; neurofilament; neurogranin; neuroimaging; neuron loss; neuropathology; neurovascular; novel; peer; pre-clinical; quality assurance; repository; resilience; resilience factor; tau Proteins; theories; tool; web-based informatics

PROJECT SUMMARY- BIOMARKER CORE (CORE G) The Biomarker Core (BMC) of the Wisconsin Alzheimer's Disease Research Center (ADRC) represents the capability and infrastructure for peering into the brain in vivo to obtain biological markers of Alzheimer's disease (AD) and related disorders and non-disease-specific qualities characterizing brain health and resilience. Since the pre-clinical time frame of AD is a major emphasis of the ADRC, and since it is increasingly understood that AD pathology occurs well before its symptoms, the charge of this core is to provide the necessary capabilities, tools, and infrastructure to investigators to characterize as accurately as possible the early in-vivo changes of AD, effect of risk and resilience factors, and effect of prevention strategies on relevant biomarkers. The core will focus on collecting, quality checking, and curating several types of AD-relevant biomarkers including a) markers indicative of AD - defined by amyloid plaques and neurofibrillary tangles, and ascertainable by molecular PET imaging or cerebrospinal fluid (CSF) assays; b) markers of cerebrovascular diseases - the second most common etiology (or etiologies) of cognitive decline and ascertainable by new MRI methods; c) markers of other neurodegenerative diseases as they become available via CSF or PET; and d) markers of general brain health including synaptic density, neuronal injury, atrophy, connectivity, inflammation, and blood flow that are possible through PET, MRI and CSF modalities. To meet these goals, we will accomplish the following aims: Aim 1: Obtain biological markers of AD's hallmark neuropathological features - amyloid plaques and neurofibrillary tangles with CSF and/or molecular PET imaging. Aim 2: Collect biomarkers of concomitant features, such as vascular disease, inflammation, and neuronal death. Aim 3: Develop method for interpreting biomarker readouts, particularly for Amyloid (A), tau (T) and neurodegeneration (N). Aim 4: Support ADRC investigators with infrastructure and analytic support. Aim 5: Share images, fluid, and derived data with the National Alzheimer's Coordinating Center (NACC), local investigators, and other qualified investigators throughout the world. Aim 6: Expand the Center's biomarker capability, including a) adopting new methods and modalities in this fast-changing field, and b) for harmonizing previously collected data or multi-site data with current or future collection methods. The BMC will work interactively with the other ADRC cores to serve the needs of the ADRC investigators as efficiently as possible and deliver high quality data to NACC and other users so we, as a field, can come to answers faster in detecting and intervening effectively in AD.

项目总结-生物标志物核心（核心G） 威斯康星州阿尔茨海默病研究中心（ADRC）的生物标志物核心（BMC）代表了 在活体内窥视大脑以获得阿尔茨海默氏症生物标记的能力和基础设施 疾病（AD）和相关疾病以及表征大脑健康的非疾病特异性质量， resilience.由于AD的临床前时间范围是ADRC的主要重点，并且由于它越来越多地被用于治疗AD， 了解AD病理发生在其症状之前，这个核心的责任是提供 必要的能力，工具和基础设施，以调查人员尽可能准确地描述 AD的早期体内变化，风险和弹性因素的影响，以及预防策略对相关 生物标志物。核心将集中在收集，质量检查，并策划几种类型的广告相关 a）指示AD的标志物-由淀粉样蛋白斑块和神经纤维缠结定义，和 可通过分子PET成像或脑脊液（CSF）测定确定; B）脑血管疾病的标志物 疾病-第二个最常见的病因（或病因）的认知能力下降，并确定了新的MRI 方法; c）其他神经退行性疾病的标志物，当它们通过CSF或PET变得可用时;和d） 一般脑健康的标志物，包括突触密度、神经元损伤、萎缩、连通性、炎症， 以及通过PET、MRI和CSF模态可能实现的血流。为了实现这些目标，我们将 实现以下目标：目标1：获得AD标志性神经病理学特征的生物标志物- 淀粉样斑块和神经纤维缠结与CSF和/或分子PET成像。目的2：收集生物标志物 伴随的特征，例如血管疾病、炎症和神经元死亡。目标3：制定方法 用于解释生物标志物读数，特别是淀粉样蛋白（A）、tau（T）和神经变性（N）。目标4： 为ADRC调查人员提供基础设施和分析支持。目标5：共享图像、流体和衍生 国家阿尔茨海默病协调中心（NACC）、当地研究人员和其他合格的研究人员 全世界的调查员。目标6：扩大中心的生物标志物能力，包括a）采用新的 方法和模式在这个快速变化的领域，和B）协调以前收集的数据或多站点 数据与当前或未来的收集方法。BMC将与其他ADRC内核交互工作， 尽可能有效地满足ADRC调查人员的需求，并向NACC提供高质量的数据， 因此，作为一个领域，我们可以更快地找到答案，有效地检测和干预AD。